Literature DB >> 35518191

Trends in Skin Melanoma Burden: Findings From the Global Burden of Disease Study.

Charalampos Siotos1, Miles W Grunvald2, George Damoulakis3, Adan Z Becerra2, Cristina M O'Donoghue2, Amir H Dorafshar1, Deana S Shenaq1.   

Abstract

Background: Melanoma is the third most common skin cancer and the leading cause of skin cancer mortality. This study sought to investigate trends in melanoma incidence, mortality, and burden of disease.
Methods: The authors assessed the records of the Global Burden of Disease Study 2017 to extract information about the incidence, mortality, and disability adjusted life years (DALY) related to melanoma during 1990-2017 in the US and other countries based on their socio-demographic index (SDI).
Results: Melanoma incidence in the US increased 1.6 times, although the difference was not statistically significant. For patients over the age of 60, the incidence was significantly increased by 1.72 to 164.6 times. Mortality was relatively stable during the study period; however, it was increased for patients over 65 years of age (range: 1.03 to 70 times), although not statistically significant. Mortality-to-incidence ratio was decreased, but the difference was not statistically significant. For patients over 75 years of age, DALYs were statistically significantly increased by 1.34 to 1.71 times. Conclusions: This study highlights differences in melanoma incidence and mortality from 1990-2017. Physicians involved in melanoma care should be aware of these changes in order to anticipate care needs.
© 2022, HMP Global. All rights reserved. Reproduction in whole or in part prohibited. Content may not be reproduced in any form without written permission. Rights, Permission, Reprint, and Translation information is available at www.hmpglobal.com.

Entities:  

Keywords:  burden; global; incidence; melanoma; mortality

Year:  2022        PMID: 35518191      PMCID: PMC9038229     

Source DB:  PubMed          Journal:  Eplasty        ISSN: 1937-5719


  17 in total

Review 1.  Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma.

Authors:  Donald L Morton
Journal:  Clin Exp Metastasis       Date:  2012-06-24       Impact factor: 5.150

2.  Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node.

Authors:  Ulrike Leiter; Rudolf Stadler; Cornelia Mauch; Werner Hohenberger; Norbert H Brockmeyer; Carola Berking; Cord Sunderkötter; Martin Kaatz; Kerstin Schatton; Percy Lehmann; Thomas Vogt; Jens Ulrich; Rudolf Herbst; Wolfgang Gehring; Jan-Christoph Simon; Ulrike Keim; Danielle Verver; Peter Martus; Claus Garbe
Journal:  J Clin Oncol       Date:  2019-09-26       Impact factor: 44.544

3.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean-Jacques Grob; Piotr Rutkowski; Christopher D Lao; C Lance Cowey; Dirk Schadendorf; John Wagstaff; Reinhard Dummer; Pier F Ferrucci; Michael Smylie; David Hogg; Andrew Hill; Ivan Márquez-Rodas; John Haanen; Massimo Guidoboni; Michele Maio; Patrick Schöffski; Matteo S Carlino; Céleste Lebbé; Grant McArthur; Paolo A Ascierto; Gregory A Daniels; Georgina V Long; Lars Bastholt; Jasmine I Rizzo; Agnes Balogh; Andriy Moshyk; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2019-09-28       Impact factor: 91.245

Review 4.  Years of potential life lost and indirect costs of melanoma and non-melanoma skin cancer: a systematic review of the literature.

Authors:  Gery P Guy; Donatus U Ekwueme
Journal:  Pharmacoeconomics       Date:  2011-10       Impact factor: 4.981

5.  Melanoma-related mortality and productivity losses in the USA, 1990-2008.

Authors:  Benjamin N Bristow; Janice Casil; Frank Sorvillo; Ricardo Basurto-Dávila; Tony Kuo
Journal:  Melanoma Res       Date:  2013-08       Impact factor: 3.599

6.  Annual report to the nation on the status of cancer, part I: National cancer statistics.

Authors:  S Jane Henley; Elizabeth M Ward; Susan Scott; Jiemin Ma; Robert N Anderson; Albert U Firth; Cheryll C Thomas; Farhad Islami; Hannah K Weir; Denise Riedel Lewis; Recinda L Sherman; Manxia Wu; Vicki B Benard; Lisa C Richardson; Ahmedin Jemal; Kathleen Cronin; Betsy A Kohler
Journal:  Cancer       Date:  2020-03-12       Impact factor: 6.921

7.  Vital signs: melanoma incidence and mortality trends and projections - United States, 1982-2030.

Authors:  Gery P Guy; Cheryll C Thomas; Trevor Thompson; Meg Watson; Greta M Massetti; Lisa C Richardson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-06-05       Impact factor: 17.586

8.  The global burden of melanoma: results from the Global Burden of Disease Study 2015.

Authors:  C Karimkhani; A C Green; T Nijsten; M A Weinstock; R P Dellavalle; M Naghavi; C Fitzmaurice
Journal:  Br J Dermatol       Date:  2017-06-12       Impact factor: 9.302

9.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001.

Authors:  O Hamid; C Robert; A Daud; F S Hodi; W J Hwu; R Kefford; J D Wolchok; P Hersey; R Joseph; J S Weber; R Dronca; T C Mitchell; A Patnaik; H M Zarour; A M Joshua; Q Zhao; E Jensen; S Ahsan; N Ibrahim; A Ribas
Journal:  Ann Oncol       Date:  2019-04-01       Impact factor: 32.976

10.  Establishing a Culture of Patient Safety, Quality, and Service in Plastic Surgery: Integrating the Fractal Model.

Authors:  Michele A Manahan; Jeffrey W Aston; Ricardo J Bello; Charalampos Siotos; Renee Demski; Carisa M Cooney; Peter J Pronovost; Gedge D Rosson
Journal:  J Patient Saf       Date:  2021-12-01       Impact factor: 2.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.